Issue |
BIO Web Conf.
Volume 75, 2023
The 5th International Conference on Bioinformatics, Biotechnology, and Biomedical Engineering (BioMIC 2023)
|
|
---|---|---|
Article Number | 05016 | |
Number of page(s) | 6 | |
Section | Big Data for Public Health Policy | |
DOI | https://doi.org/10.1051/bioconf/20237505016 | |
Published online | 15 November 2023 |
Risk of Adverse Drug-Drug Interactions in Heart Failure Patients with Co-morbidity Chronic Kidney Disease Prescribed Polypharmacy
1 School of Medicine (Clinical Program), Faculty of Medicine, Universitas Lambung Mangkurat, Banjarmasin, Indonesia
2 Department of Pharmacology, School of Medicine (Academic Program), Faculty of Medicine, Universitas Lambung Mangkurat, Banjarmasin, Indonesia
3 Department of Cardiology, Faculty of Medicine, Universitas Lambung Mangkurat, Banjarmasin, Indonesia
4 Department of Cardiology and Vascular Medicine, Ulin Public Hospital, Banjarmasin, Indonesia
5 Department of Medical Education, School of Medicine (Academic Program), Faculty of Medicine, Universitas Lambung Mangkurat, Banjarmasin, Indonesia
* Corresponding email: bakhriansyah@gmail.com
Heart failure (HF) is a complex clinical syndrome due to the impairment of myocardial function, valvular or pericardial diseases, or anything interfering blood flow leading to fluid retention. A comorbidity that can accompany HF patients is chronic kidney disease (CKD). This condition requires consumption of several drugs simultaneously (polypharmacy). This study aimed to determine the risk of adverse drug-drug interactions in HF patients with co-morbid CKD prescribed polypharmacy. This is an analytic observational study with a cross-sectional approach in the Cardiac Outpatient Clinic of Ulin Public Hospital, Banjarmasin using medical records from 2020-2021. The interactions were determined using the UpToDate® under the Lexicomp tool. Prevalence Odds Ratio (POR) and 95% Confidence Intervals (95%CI) were determined using Logistic Regression analysis. Of 27 patients, 17 were males (62.96%). Most of the interactions (92.92%) were under category C and the moderate category (82 interactions, 82.83%). For HF patients with CKD, polypharmacy increased the risk of adverse drug-drug interactions by 2.75 times compared to those who were not prescribed polypharmacy, but it was not statistically significant (crude POR 2.75, 95% CI; 0.248-30.512). In conclusion, there is no significant relationship between polypharmacy and the risk of adverse drug-drug interactions in HF patients with CKD.
Key words: polypharmacy / drug-drug interactions / heart failure / chronic kidney disease / Ulin Public Hospital / Banjarmasin
© The Authors, published by EDP Sciences, 2023
This is an Open Access article distributed under the terms of the Creative Commons Attribution License 4.0, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.
Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.
Initial download of the metrics may take a while.